LG Technology Ventures
2755 Great America Way Suite #425, Santa Clara, CA, 95054, United States
Overview
LG Technology Ventures was established in 2018 and is the venture capital investment arm of the LG Group of South Korea. The LG Technology Ventures team consists of experienced investors, entrepreneurs, technologists, and industry domain experts. Currently, LG Technology Ventures is managing over $400 million of fund assets and invests in early-stage information technology, automotive, manufacturing, life sciences, energy, and advanced materials companies. They strive to create value for their portfolio companies by helping them develop strategic partnerships with various LG Companies.
- Total investments
- 51
- Lead investments
- 7
- Investments · 12mo
- 11
- Active investors
- 8
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Zenity
Participated · Series C · Aug 2026
Zenity builds a platform that gives security teams visibility, enforcement and response capabilities specifically for AI agents, allowing deterministic blocking, modification or allowance of agent actions by understanding intent. The company serves a majority of customers in the Fortune 500, Global 2000 and highly regulated industries such as financial services, healthcare, pharmaceuticals, energy and manufacturing. Zenity operates Zenity Labs, whose research has uncovered industry-defining vulnerabilities—examples include AgentFlayer and other disclosed flaws in agentic frameworks and integrations. The company has more than 230 employees, with R&D centered in Tel Aviv and go-to-market and operations led from New York. Financially, Zenity reported tripling revenue in each of the past two years and said it is on track to triple revenue again this year. Going forward, Zenity plans to use its new funding to accelerate platform innovation, expand Zenity Labs and grow its global footprint, particularly across Europe and Asia Pacific.
- Spectro Cloud
Participated · Series D · Jul 2026
Spectro Cloud offers PaletteAI, a platform designed to help organizations deploy and operate production AI infrastructure across GPU clusters, Kubernetes, VMs, edge locations, regulated systems and air-gapped facilities. PaletteAI combines full-stack lifecycle management, multi-silicon and multi-model support, and governance features intended to improve utilization, control token costs and enforce policies. The company launched PaletteAI in October 2025 and has customers that include T-Mobile, Airbus, the U.S. Air Force and Yum! Brands, as well as neocloud and sovereign cloud operators. Spectro Cloud participates in NVIDIA-validated AI factory architectures and the NVIDIA IGX and Jetson ecosystems, and it works with chipmakers, hardware vendors, systems integrators and distributors. The company plans to expand international sales and customer support, particularly across EMEA and APAC, and to deepen partnerships across the AI infrastructure stack. With the Series D, Spectro Cloud has now raised a total of $260 million in disclosed capital.
- Fore Biotherapeutics
Participated · Series D · Jul 2026
FORE Biotherapeutics is a registration-stage targeted oncology company whose lead asset is plixorafenib (FORE8394; formerly PLX8394), a BRAF inhibitor with a mechanism described as both a dimer and paradox breaker. The company is advancing plixorafenib in the global Phase 2 FORTE Master Protocol, a registration-intended basket study that includes monotherapy baskets for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions. Fore reported that target enrollment of approximately 50 patients has been reached in the BRAF V600E CNS tumor basket and expects topline results from that basket around the end of 2026; the company anticipates a potential regulatory submission if the primary analysis is positive. Plixorafenib received Breakthrough Therapy Designation from the FDA in April 2026, and prior Phase 1/2 data showed a 67% ORR in MAPK inhibitor–naïve BRAF V600 primary recurrent CNS tumors (n=9) and a 42% response rate with a median duration of response of 17.8 months in V600-altered, MAPK inhibitor–naïve patients. The company reported a favorable safety profile for plixorafenib, including a drug-related discontinuation rate of less than 2%, and has implemented protocol changes in FORTE such as allowing dosing with food and lowering the minimum enrollment age to 8 years based on IDMC clearance.
- Config
Participated · Seed · May 2026
Config records humans performing physical tasks in controlled studio environments and in the field, then converts that data to better suit robotic motion and interaction. The company operates data production out of Seoul and Hanoi with a workforce of nearly 300 and has accumulated over 100,000 hours of human motion data. Config’s approach emphasizes transforming data before training so models work more effectively for robots rather than retraining models on mismatched data. The startup counts large manufacturers, system integrators, and customers in agriculture and defense as current customers and is already generating revenue. Founded in January 2025 by CEO Minjoon Seo and three co-founders with backgrounds at Meta, Waymo, Google and Naver, Config plans to scale to one million hours of data, grow enterprise ARR to $10 million by end of 2027, and launch a cloud-based Robot-as-a-Service offering.
- Astrocade AI
Participated · Series A · May 2026
Astrocade offers an interactive platform that leverages generative AI to turn ideas into playable games in minutes and hosts a social gaming community. The company reports over 20 million users who engage with interactive worlds, educational adventures, and AI-powered companions. Leadership includes CEO Amir Sadeghian, CTO Ali Sadeghian, and CSO Fei‑Fei Li. Following the $56M combined Series A/B raise, Astrocade plans to expand its team, invest further in its community, deepen its generative AI capabilities (including AI agents for coding and asset creation), and scale globally to support increased user demand. The articles do not provide revenue figures or a disclosed valuation.